Company Filing History:
Years Active: 2013
Title: Gérald Batist: Innovator of Anticancer Agents
Introduction
Gérald Batist is an esteemed inventor based in Montreal, Canada, known for his contributions to the field of oncology. His innovative work in synthesizing novel hybrid-ionone and curcumin molecules has shown promise in the fight against various types of cancer.
Latest Patents
He holds a patent for "Hybrid-ionone and curcumin molecules as anticancer agents." This significant invention relates to the synthesis of a series of ionone and curcumin derivatives designed as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. The patent outlines the development of bifunctional antiandrogens that inhibit both androgen receptors (AR) and IKB kinases (IKK). His research demonstrated the in vitro cytotoxicity of these synthesized ionone-based chalcones against prostate cancer cell lines, showcasing substantial antiproliferative activities in prostate, breast, and lung cancer cell lines.
Career Highlights
Gérald Batist is affiliated with Trt Pharma Inc., where he has dedicated his expertise towards cancer research and the development of innovative therapeutic solutions. His contributions to scientific literature and patent filings underscore his commitment to advancing oncological treatments.
Collaborations
In his professional journey, Gérald Batist has collaborated with notable colleagues Jian Hui Wu and Jinming Zhou. Together, they have worked on various projects aimed at enhancing the efficacy of cancer therapies through innovative molecular designs.
Conclusion
Gérald Batist's work in developing hybrid-ionone and curcumin molecules represents a significant stride in the quest for effective cancer treatments. His patent and collaboration efforts at Trt Pharma Inc. not only highlight his innovative spirit but also contribute to the broader scientific community's fight against cancer. As ongoing research continues, his contributions may lead to groundbreaking advancements in cancer therapeutics.